Theravance Biopharma presents positive preliminary data for Vibativ

Theravance Biopharma has announced positive new data from multiple studies of Vibativ (telavancin), a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency.

Preliminary data from the ongoing TOUR study show positive clinical responses for Vibativ treatment ranging from 64.9% to 72.6% in each of these infection types.

Positive clinical response was defined as cure or improvement leading to step-down oral therapy.

The company says it will present additional collections of data at upcoming meetings.